Download PDF
J Reconstr Microsurg 2018; 34(09): 729-734
DOI: 10.1055/s-0038-1655735
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Adequacy of Fixed-Dose Heparin Infusions for Venous Thromboembolism Prevention after Microsurgical Procedures

Corinne M. Bertolaccini
1   Department of Pharmacy Services, University of Utah Health, Salt Lake City, Utah
,
Ann Marie B. Prazak
1   Department of Pharmacy Services, University of Utah Health, Salt Lake City, Utah
,
Jayant Agarwal
2   Division of Plastic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah
,
Isak A. Goodwin
2   Division of Plastic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah
,
W. Bradford Rockwell
2   Division of Plastic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah
,
Christopher J. Pannucci
2   Division of Plastic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah
› Author Affiliations
Further Information

Publication History

20 December 2017

22 March 2018

Publication Date:
22 May 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background In microvascular surgery, patients often receive unfractionated heparin infusions to minimize risk for microvascular thrombosis. Patients who receive intravenous (IV) heparin are believed to have adequate prophylaxis against venous thromboembolism (VTE). Whether a fixed dose of IV heparin provides detectable levels of anticoagulation, or whether the “one size fits all” approach provides adequate prophylaxis against VTE remains unknown. This study examined the pharmacodynamics of fixed-dose heparin infusions and the effects of real-time, anti-factor Xa (aFXa) level driven heparin dose adjustments.

Methods This prospective clinical trial recruited adult microvascular surgery patients placed on a fixed-dose (500 units/h) unfractionated heparin infusion during their initial microsurgical procedure. Steady-state aFXa levels, a marker of unfractionated heparin efficacy and safety, were monitored. Patients with out-of-range aFXa levels received protocol-driven real-time dose adjustments. Outcomes of interest included aFXa levels in response to heparin 500 units/h, number of dose adjustments required to achieve goal aFXa levels, time to reach goal aFXa level, and 90-day clinically relevant bleeding and VTE.

Results Twenty patients were recruited prospectively. None of 20 patients had any detectable level of anticoagulation in response to heparin infusions at 500 units/h. The median number of dose adjustments required to reach goal level was five, and median weight-based dose to reach goal level was 11.8 units/kg/h. Real-time dose adjustments significantly increased the proportion of patients with in-range levels (60 vs. 0%, p = 0.0001). The 90-day VTE rate was 5% and 90-day clinically relevant bleeding rate was 5%.

Conclusions Fixed-dose heparin infusions at a rate of 500 units/h do not provide a detectable level of anticoagulation after microsurgical procedures and are insufficient for the majority of patients who require VTE prophylaxis. Weight-based heparin infusions at 10 to 12 units/kg/h deserve future study in patients undergoing microsurgical procedures to increase the proportion of patients receiving adequate VTE prophylaxis.

Keywords

heparin - plastic surgery - microvascular surgery - venous thromboembolism - anti-factor Xa
 

  • References

  • 1 Swartz JE, Aarts MC, Swart KM. , et al. The value of postoperative anticoagulants to improve flap survival in the free radial forearm flap: a systematic review and retrospective multicentre analysis. Clin Otolaryngol 2015; 40 (06) 600-609
    CrossrefPubMedGoogle Scholar
  • 2 Cigna E, Lo Torto F, Maruccia M. , et al. Postoperative care in finger replantation: our case-load and review of the literature. Eur Rev Med Pharmacol Sci 2015; 19 (14) 2552-2561
    PubMedGoogle Scholar
  • 3 Glicksman A, Ferder M, Casale P, Posner J, Kim R, Strauch B. 1457 years of microsurgical experience. Plast Reconstr Surg 1997; 100 (02) 355-363
    CrossrefPubMedGoogle Scholar
  • 4 Kroll SS, Schusterman MA, Reece GP. , et al. Timing of pedicle thrombosis and flap loss after free-tissue transfer. Plast Reconstr Surg 1996; 98 (07) 1230-1233
    CrossrefPubMedGoogle Scholar
  • 5 Pršić A, Kiwanuka E, Caterson SA, Caterson EJ. Anticoagulants and statins as pharmacological agents in free flap surgery: current rationale. Eplasty 2015; 15: e51
    PubMedGoogle Scholar
  • 6 Cannady SB, Hatten K, Wax MK. Postoperative controversies in the management of free flap surgery in the head and neck. Facial Plast Surg Clin North Am 2016; 24 (03) 309-314
    CrossrefPubMedGoogle Scholar
  • 7 Pannucci CJ, Bailey SH, Dreszer G. , et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. J Am Coll Surg 2011; 212 (01) 105-112
    CrossrefPubMedGoogle Scholar
  • 8 Pannucci CJ, Dreszer G, Wachtman CF. , et al. Postoperative enoxaparin prevents symptomatic venous thromboembolism in high-risk plastic surgery patients. Plast Reconstr Surg 2011; 128 (05) 1093-1103
    CrossrefPubMedGoogle Scholar
  • 9 Pannucci CJ, Prazak AM, Scheefer M. Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis. Am J Surg 2017; 213 (06) 1143-1152
    CrossrefPubMedGoogle Scholar
  • 10 Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res 2011; 32 (01) 1-5
    CrossrefPubMedGoogle Scholar
  • 11 Wall V, Fleming KI, Tonna JE. , et al. Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose. Am J Surg 2017; DOI: 10.1016/j.amjsurg.2017.07.014.
    CrossrefPubMedGoogle Scholar
  • 12 Clark NP, Delate T, Cleary SJ, Witt DM. Unfractionated heparin dose requirements targeting intermediate intensity antifactor Xa concentration during pregnancy. Pharmacotherapy 2010; 30 (04) 369-374
    CrossrefPubMedGoogle Scholar
  • 13 Cheng SS, Nordenholz K, Matero D. , et al. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med 2012; 38 (04) 642-648
    CrossrefPubMedGoogle Scholar
  • 14 Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51 (2–3): 70-78
    CrossrefPubMedGoogle Scholar
  • 15 Ramanathan R, Gu Z, Limkemann AJ. , et al. Association between interruptions in chemical prophylaxis and VTE formation. Am Surg 2015; 81 (07) 732-737
    CrossrefPubMedGoogle Scholar
  • 16 Chien W, Varvares MA, Hadlock T, Cheney M, Deschler DG. Effects of aspirin and low-dose heparin in head and neck reconstruction using microvascular free flaps. Laryngoscope 2005; 115 (06) 973-976
    CrossrefPubMedGoogle Scholar
  • 17 Kroll SS, Miller MJ, Reece GP. , et al. Anticoagulants and hematomas in free flap surgery. Plast Reconstr Surg 1995; 96 (03) 643-647
    CrossrefPubMedGoogle Scholar
  • 18 Nikolis A, Tahiri Y, St-Supery V. , et al. Intravenous heparin use in digital replantation and revascularization: the Quebec Provincial Replantation program experience. Microsurgery 2011; 31 (06) 421-427
    CrossrefPubMedGoogle Scholar
  • 19 Nelson JA, Chung CU, Bauder AR, Wu LC. Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: a novel anticoagulation protocol. J Plast Reconstr Aesthet Surg 2017; 70 (03) 307-312
    CrossrefPubMedGoogle Scholar
  • 20 Pannucci CJ, Rockwell WB, Ghanem M, Fleming KI, Momeni A, Agarwal J. Inadequate enoxaparin dosing predicts 90-day venous thromboembolism risk among plastic surgery inpatients: an examination of enoxaparin pharmacodynamics. Plast Reconstr Surg 2017; 139 (04) 1009-1020
    CrossrefPubMedGoogle Scholar
  • 21 Ko A, Harada MY, Barmparas G. , et al. Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinicall evident venous thromboembolism after trauma. JAMA Surg 2016; 151 (11) 1006-1013
    CrossrefPubMedGoogle Scholar
  • 22 Malinoski D, Ewing T, Patel MS. , et al. Risk factors for venous thromboembolism in critically ill trauma patients who cannot receive chemical prophylaxis. Injury 2013; 44 (01) 80-85
    CrossrefPubMedGoogle Scholar
  • 23 Hirsh J, Levine M. Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. Br J Clin Pract Suppl 1989; 65: 2-8
    PubMedGoogle Scholar
  • 24 Sutzko DC, Georgoff PE, Obi AT, Healy MA, Osborne NH. The association of venous thromboembolism chemoprophylaxis timing on venous thromboembolism after major vascular surgery. J Vasc Surg 2018; 67 (01) 262-271e
    CrossrefPubMedGoogle Scholar